Polypill for cardiovascular disease prevention.

Polypill for cardiovascular disease prevention.

Opis bibliograficzny
1. autor:	Dalton, A
Format:	Journal article
Język:	English
Wydane:	2013

Podobne zapisy

The Concept of the Polypill in the Prevention of Cardiovascular Disease
od: Brandon Wiley, i wsp.
Wydane: (2014-04-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
od: Mant, J, i wsp.
Wydane: (2021)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
od: Apichard Sukonthasarn, i wsp.
Wydane: (2021-03-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
od: J. Masjuan, i wsp.
Wydane: (2021-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
od: Samaneh Noroozi, i wsp.
Wydane: (2021-04-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
od: Omneya A. Kandil, i wsp.
Wydane: (2022-04-01)

The polypill: the solution for prevention of coronary heart disease?
od: Hendarto Natadidjaja
Wydane: (2016-02-01)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
od: Николай Владимирович Абрамов, i wsp.
Wydane: (2024-02-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
od: Ramin Ravangard, i wsp.
Wydane: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
od: Lilian Grigorian-Shamagian, i wsp.
Wydane: (2021-08-01)

The use of polypills in cardiovascular disease management: Benefits vs challenges
od: Yamaan Adil, i wsp.
Wydane: (2024-09-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
od: Lopez-Lopez JP, i wsp.
Wydane: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
od: Gunaratne Padma S, i wsp.
Wydane: (2011-01-01)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
od: Gautam Satheesh, i wsp.
Wydane: (2024-07-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
od: Siddharth Birla, i wsp.
Wydane: (2023-09-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
od: Massimo F. Piepoli
Wydane: (2005-06-01)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
od: Gautam Satheesh, i wsp.
Wydane: (2024-08-01)

Preventing the progression of climate change: one drug or polypill?
od: Hugh Montgomery
Wydane: (2017-03-01)

Polypill holds promise for people with chronic disease
od: Jacqui Wise
Wydane: (2005-12-01)

Polypill" conception in modern cardiology
od: I E Chazova, i wsp.
Wydane: (2018-12-01)

Polypill revisited – Unity in diversity
od: Gheorghe-Andrei Dan, i wsp.
Wydane: (2020-08-01)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
od: Carlos Aguiar, i wsp.
Wydane: (2022-11-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
od: Reza Jahangiri, i wsp.
Wydane: (2022-01-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
od: Cordero A, i wsp.
Wydane: (2023-07-01)

Three-dimensional printing of flexible polypill
od: Yasir Karkar, i wsp.
Wydane: (2023-12-01)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
od: Jowett, S, i wsp.
Wydane: (2017)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
od: Sue Jowett, i wsp.
Wydane: (2017-01-01)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
od: Zhu LL, i wsp.
Wydane: (2023-09-01)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
od: Lopez-Jaramillo P, i wsp.
Wydane: (2023-10-01)

Has the polypill finally proven its worth?
od: Treadwell, J
Wydane: (2019)

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
od: Anubha Agarwal, i wsp.
Wydane: (2024-02-01)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
od: José Alejandro Chávez Fernández, i wsp.
Wydane: (2023-01-01)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
od: Usherwood Tim, i wsp.
Wydane: (2010-08-01)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
od: Virdee, S, i wsp.
Wydane: (2013)

Effect of a Cardiovascular Polypill on Poststroke Cognition Among Ghanaians: Secondary Analysis of a Randomized Clinical Trial
od: Fred Stephen Sarfo, i wsp.
Wydane: (2024-08-01)

Randomized Polypill crossover trial in people aged 50 and over.
od: David S Wald, i wsp.
Wydane: (2012-01-01)

Polypill therapy and frailty in elderly: Time to stop treating everything
od: Sunil Kumar, i wsp.
Wydane: (2021-04-01)

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.
od: C Raina Elley, i wsp.
Wydane: (2012-01-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
od: Hae Won Jung, i wsp.
Wydane: (2023-09-01)

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
od: PILL Collaborative Group, i wsp.
Wydane: (2011-01-01)